Status:
TERMINATED
Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain
Lead Sponsor:
Jewish General Hospital
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Treprostinil subcutaneous (under the skin) infusion is a very good medication for treating pulmonary arterial hypertension but infusion site pain may be very severe in some patients. The investigators...
Eligibility Criteria
Inclusion
- PAH
- Treprostinil treatment for at least 3 months
- Severe infusion site pain
Exclusion
- Pregnancy/breastfeeding
- Decompensated heart failure
- Chronic liver disease
- Abnormal electrolytes
- Heart block (2/3 degree), sino-atrial block, idioventricular rhythm
- Systolic systemic BP \<90mmHg
- Bradycardia HR \<55
- Adverse reaction to lidocaine or other amide local anesthestic
- Interacting medications (anti-arrhythmics, CYP1A2 inhibitors)
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01433328
Start Date
January 1 2012
End Date
April 1 2012
Last Update
February 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2